Platelet Rich Plasma Injections for Vulvar Lichen Sclerosus

15 patients with biopsy proven active vulvar lichen sclerosus will be recruited by a clinic specializing in vulvar disorders. This study consists of a 2 week screening period and a 12-week treatment period. Participants will receive two separate treatments of autologous platelet rich plasma separated by 6 weeks. A repeat biopsy will be performed 6 weeks after the second autologous platelet rich plasma injection

15 patients with biopsy proven active vulvar lichen sclerosus will be recruited by a clinic specializing in vulvar disorders. This study consists of a 2 week screening period. A 4mm vulvar punch biopsy will be obtained at the initiation of the screening period to confirm that the participant have active lichen sclerosus. 12 weeks after the biopsy, the participants will receive an injection of 5cc of autologous platelet rich plasma into the affected vulvar skin. Six weeks later, participants will receive an additional injection of 5cc of autologous platelet rich plasma. A repeat biopsy will be performed 6 weeks after the second autologous platelet rich plasma injection. The inflammation on both biopsy specimens will be determined by a dermatopathologist.

Autologous platelet rich plasma injection into vulvar skin. There are no placebo, sham, or active comparator arms

5cc of autologous platelet rich plasma derived from 50cc of whole blood will be injected into vulvar skin.

Participants will fill out a 10cm visual analogue scale that grade the amount of their pruritus (itching)

The investigator will rate the severity of lichen sclerosus based on the amount of lichenification, fissures, and ulceration. This will be a 4 point scale.

Inclusion Criteria: Active lichen sclerosus no current treatment symptomatic 4/10 on visual analogue scale Exclusion Criteria: history of vulvar carcinoma or VIN